Mikael Gerling Engmark is specialized in biological data analysis
and mammalian cell cultivation. He holds an M.Sc.Eng in Medicinal Chemistry from the Technical University of Denmark (DTU) and has completed the BioBusiness and Innovation Program at Copenhagen Business School. Currently, he is a PhD student at DTU Bioinformatics
investigating cross-reactivity of snakebite antivenom using high density peptide microarray technology. The end goal of his research is development of recombinant antibodies each capable of binding and neutralizing multiple related toxins. The funding for
his PhD was raised by Mikael himself and obtained from the Novo Nordisk Foundation. Mikael has experience from Novo Nordisk and NeuroSearch, is a co-founder of VenomAb (Danish Entrepreneurship Award 2013), has been employed as a researcher to investigate innovation
targeted research in an interdisciplinary consortium of Danish universities, has been the Vice President of the Society of Biological Engineering, and has won the Global Management Challenge (GMC) Denmark and achieved an international 9th place in Russia (World’s
largest competition within business strategy). Mikael holds awards for great engineering skills (Boston Consulting Group 2011) and his master thesis (Oticon foundation scholarship 2012).